New research shows that improvements in kidney function outcomes with GLP-1 receptor agonists in patients with type 2 diabetes extend to overweight or obese individuals without diabetes. A study presented at the ERA Congress 2024 analyzed data from the SELECT trial, which included adults with pre-existing cardiovascular disease who were overweight but did not have diabetes. The results showed that those treated with semaglutide had a reduced risk of developing kidney complications compared to the placebo group. The findings suggest potential benefits of GLP-1 agonists in primary prevention of chronic kidney disease in high-risk individuals without diabetes.
Source link
Semaglutide Kidney Benefits Extend to Those Without Diabetes
